Mark S. Schlissel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark S. Schlissel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Stacey R. Dillon
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
3 shared publicationsAlan P. Wolffe
Laboratory of Molecular Embryology, National Institute of Child Health and Human Development, NIH Bethesda MD 20892 USA
1 shared publication- Amit Golding
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
1 shared publication Andrei Constantinescu
Departments of Medicine, Molecular Biology and Genetics, and Oncology, Division of Rheumatology, Johns Hopkins University School of Medicine , Baltimore, MD 21205
1 shared publicationAntony Rosen
Departments of Medicine, Molecular Biology and Genetics, and Oncology, Division of Rheumatology, Johns Hopkins University School of Medicine , Baltimore, MD 21205
1 shared publicationChulho Kang
University of California, Berkeley, Division of Immunology, Department of Molecular and Cell Biology, Berkeley, CA 94720
1 shared publication
Latest Publications
- Open Access
- 8 March 2004
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 199 (6) , 825-830
Pax5 Activates Immunoglobulin Heavy Chain V to DJ Rearrangement in Transgenic Thymocytes
Mice deficient for the B cell–restricted transcription factor Pax5 show a defect in the VH to DJH rearrangement step of immunoglobulin heavy chain gene assembly even though the expression of the V(D)J recombinase is not diminished in Pax5−/− pro–B cells. To investigate whether Pax5 is limiting for VH to DJH rearrangement, we generated transgenic mice which express Pax5 in developing thymocytes. We show that enforced expression of Pax5 in thymocytes results in a partial block in T cell development due to defective pre-TCR signaling in β-selection. Moreover, our results demonstrate that expression of Pax5 in early thymocytes is sufficient to induce VH to DJH rearrangements in CD4+CD8+ T cells and lead us to suggest that Pax5 may play a direct role in the lineage-specific regulation of immunoglobulin heavy chain gene rearrangement.
- 8 March 2004
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 199 (6) , 825-830
Open AccessPax5 Activates Immunoglobulin Heavy Chain V to DJ Rearrangement in Transgenic Thymocytes
Mice deficient for the B cell–restricted transcription factor Pax5 show a defect in the VH to DJH rearrangement step of immunoglobulin heavy chain gene assembly even though the expression of the V(D)J recombinase is not diminished in Pax5−/− pro–B cells. To investigate whether Pax5 is limiting for VH to DJH rearrangement, we generated transgenic mice which express Pax5 in developing thymocytes. We show that enforced expression of Pax5 in thymocytes results in a partial block in T cell development due to defective pre-TCR signaling in β-selection. Moreover, our results demonstrate that expression of Pax5 in early thymocytes is sufficient to induce VH to DJH rearrangements in CD4+CD8+ T cells and lead us to suggest that Pax5 may play a direct role in the lineage-specific regulation of immunoglobulin heavy chain gene rearrangement.
- 1 November 2003
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 3 (11) , 890-899
Regulating antigen-receptor gene assembly
- 1 November 2003
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 3 (11) , 890-899
Regulating antigen-receptor gene assembly
- 1 September 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (9) , 817-819
How pre-B cells know when they have it right
- 1 September 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (9) , 817-819
How pre-B cells know when they have it right
- 30 April 2003
- Published by Elsevier in Current Opinion in Immunology
- Vol. 15 (2) , 155-157
Lymphocyte development
- 30 April 2003
- Published by Elsevier in Current Opinion in Immunology
- Vol. 15 (2) , 155-157
Lymphocyte development
- Open Access
- 1 August 2002
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 14 (8) , 893-904
Partial restoration of B cell development in Jak-3-/- mice achieved by co-expression of IgH and Emicro-myc transgenes
Jak‐3 is a non‐receptor tyrosine kinase that plays an important role in coordinating signals received through a wide range of cytokine receptors, including the IL‐7 receptor (IL‐7R). Jak‐3‐deficient mice have a profound block in B cell development at the pro‐to‐pre‐B cell transition and have very few peripheral B cells. This block has been postulated to reflect the inability of Jak‐3–/– pro‐B cells to respond to IL‐7. Here we demonstrate that B cell development can be partially restored in Jak‐3‐deficient mice when they are bred to mice carrying both a rearranged Ig heavy chain (IgH/Igµ) transgene and a c‐myc transgene expressed in the B cell lineage. Jak‐3–/– mice expressing both of these transgenes exhibit significant increases in the number of B cells in the bone marrow and, to a lesser extent, in the spleen. However, very few rescued B cells were detectable in mice greater than 4 months of age. To determine whether resident hyperactivated Jak‐3–/– peripheral T cells are responsible for the elimination of the rescued B cells in older mice, we bred IgH transgenic (Igµ Tg)/myc Tg/Jak‐3–/– mice to T cell‐deficient (TCRα–/–) mice. Data from these experiments suggest that the paucity of B cells in older Jak‐3–/– mice is largely attributable to the lack of Jak‐3 in the B cells themselves. Thus, Jak‐3 seems to play several important roles in B cells: during development, to enable cell division, Ig gene rearrangement and cell differentiation, and in mature cells, to promote B cell survival in the periphery.
- 1 August 2002
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 14 (8) , 893-904
Open AccessPartial restoration of B cell development in Jak-3-/- mice achieved by co-expression of IgH and Emicro-myc transgenes
Jak‐3 is a non‐receptor tyrosine kinase that plays an important role in coordinating signals received through a wide range of cytokine receptors, including the IL‐7 receptor (IL‐7R). Jak‐3‐deficient mice have a profound block in B cell development at the pro‐to‐pre‐B cell transition and have very few peripheral B cells. This block has been postulated to reflect the inability of Jak‐3–/– pro‐B cells to respond to IL‐7. Here we demonstrate that B cell development can be partially restored in Jak‐3‐deficient mice when they are bred to mice carrying both a rearranged Ig heavy chain (IgH/Igµ) transgene and a c‐myc transgene expressed in the B cell lineage. Jak‐3–/– mice expressing both of these transgenes exhibit significant increases in the number of B cells in the bone marrow and, to a lesser extent, in the spleen. However, very few rescued B cells were detectable in mice greater than 4 months of age. To determine whether resident hyperactivated Jak‐3–/– peripheral T cells are responsible for the elimination of the rescued B cells in older mice, we bred IgH transgenic (Igµ Tg)/myc Tg/Jak‐3–/– mice to T cell‐deficient (TCRα–/–) mice. Data from these experiments suggest that the paucity of B cells in older Jak‐3–/– mice is largely attributable to the lack of Jak‐3 in the B cells themselves. Thus, Jak‐3 seems to play several important roles in B cells: during development, to enable cell division, Ig gene rearrangement and cell differentiation, and in mature cells, to promote B cell survival in the periphery.
- 1 June 2002
- Published by Elsevier in Seminars in Immunology
- Vol. 14 (3) , 207-212
Allelic exclusion of immunoglobulin gene rearrangement and expression: why and how?
- 1 June 2002
- Published by Elsevier in Seminars in Immunology
- Vol. 14 (3) , 207-212
Allelic exclusion of immunoglobulin gene rearrangement and expression: why and how?
- Open Access
- 1 January 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 166 (1) , 58-71
Annexin V Binds to Positively Selected B Cells
Recombinant annexin V (rAnV) has been used in flow cytometry to identify cells undergoing apoptosis, based on its ability to bind to phosphatidylserine, a negatively charged lipid normally restricted to the cytoplasmic face of the plasma membrane but externalized early during apoptosis. When we stained murine bone marrow (BM) cells with fluorescently labeled rAnV, we found that a surprisingly large fraction of BM B cells bearing selectable transgenic Ag receptors bind significant amounts of rAnV, but that these cells are not apoptotic. Here, we show that binding of rAnV to developing B cells in normal mice correlates with B cell receptor-dependent selection events at several stages of development within both B-1 and B-2 cell subsets. In fact, nearly all B-1 B cells and splenic marginal zone B cells bind rAnV, suggesting that the externalization of phosphatidylserine occurs once mature B cells are selected through BCR-mediated signaling. However, this plasma membrane alteration is apparently not shared by all lymphocytes, because we did not find a parallel population of rAnV-binding viable T cells in vivo in normal or TCR transgenic mice. We also show that BM stromal cell lines can influence the extent of rAnV binding by viable BM B cells during coculture in vitro. We suggest that rAnV detects a potentially important membrane alteration that occurs as B cells develop in the BM and are readied for export to the peripheral lymphoid organs and again among mature B cells recruited to the marginal zone or the B-1 compartment.
- 1 January 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 166 (1) , 58-71
Open AccessAnnexin V Binds to Positively Selected B Cells
Recombinant annexin V (rAnV) has been used in flow cytometry to identify cells undergoing apoptosis, based on its ability to bind to phosphatidylserine, a negatively charged lipid normally restricted to the cytoplasmic face of the plasma membrane but externalized early during apoptosis. When we stained murine bone marrow (BM) cells with fluorescently labeled rAnV, we found that a surprisingly large fraction of BM B cells bearing selectable transgenic Ag receptors bind significant amounts of rAnV, but that these cells are not apoptotic. Here, we show that binding of rAnV to developing B cells in normal mice correlates with B cell receptor-dependent selection events at several stages of development within both B-1 and B-2 cell subsets. In fact, nearly all B-1 B cells and splenic marginal zone B cells bind rAnV, suggesting that the externalization of phosphatidylserine occurs once mature B cells are selected through BCR-mediated signaling. However, this plasma membrane alteration is apparently not shared by all lymphocytes, because we did not find a parallel population of rAnV-binding viable T cells in vivo in normal or TCR transgenic mice. We also show that BM stromal cell lines can influence the extent of rAnV binding by viable BM B cells during coculture in vitro. We suggest that rAnV detects a potentially important membrane alteration that occurs as B cells develop in the BM and are readied for export to the peripheral lymphoid organs and again among mature B cells recruited to the marginal zone or the B-1 compartment.
- 1 December 2000
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 20 (24) , 9203-9211
c-Myb Binds to a Sequence in the Proximal Region of the RAG-2 Promoter and Is Essential for Promoter Activity in T-Lineage Cells
The RAG-2 gene encodes a component of the V(D)J recombinase which is essential for the assembly of antigen receptor genes in B and T lymphocytes. Previously, we reported that the transcription factor BSAP (PAX-5) regulates the murine RAG-2 promoter in B-cell lines. A partially overlapping but distinct region of the proximal RAG-2 promoter was also identified as an important element for promoter activity in T cells; however, the responsible factor was unknown. In this report, we present data demonstrating that c-Myb binds to a Myb consensus site within the proximal promoter and is critical for its activity in T-lineage cells. We show that c-Myb can transactivate a RAG-2 promoter-reporter construct in cotransfection assays and that this transactivation depends on the proximal promoter Myb consensus site. By using a chromatin immunoprecipitation (ChIP) strategy, fractionation of chromatin with anti-c-Myb antibody specifically enriched endogenous RAG-2 promoter DNA sequences. DNase I genomic footprinting revealed that the c-Myb site is occupied in a tissue-specific fashion in vivo. Furthermore, an integrated RAG-2 promoter construct with mutations at the c-Myb site was not enriched in the ChIP assay, while a wild-type integrated promoter construct was enriched. Finally, this lack of binding of c-Myb to a chromosomally integrated mutant RAG-2 promoter construct in vivo was associated with a striking decrease in promoter activity. We conclude that c-Myb regulates the RAG-2 promoter in T cells by binding to this consensus c-Myb binding site.
- 1 December 2000
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 20 (24) , 9203-9211
c-Myb Binds to a Sequence in the Proximal Region of the RAG-2 Promoter and Is Essential for Promoter Activity in T-Lineage Cells
The RAG-2 gene encodes a component of the V(D)J recombinase which is essential for the assembly of antigen receptor genes in B and T lymphocytes. Previously, we reported that the transcription factor BSAP (PAX-5) regulates the murine RAG-2 promoter in B-cell lines. A partially overlapping but distinct region of the proximal RAG-2 promoter was also identified as an important element for promoter activity in T cells; however, the responsible factor was unknown. In this report, we present data demonstrating that c-Myb binds to a Myb consensus site within the proximal promoter and is critical for its activity in T-lineage cells. We show that c-Myb can transactivate a RAG-2 promoter-reporter construct in cotransfection assays and that this transactivation depends on the proximal promoter Myb consensus site. By using a chromatin immunoprecipitation (ChIP) strategy, fractionation of chromatin with anti-c-Myb antibody specifically enriched endogenous RAG-2 promoter DNA sequences. DNase I genomic footprinting revealed that the c-Myb site is occupied in a tissue-specific fashion in vivo. Furthermore, an integrated RAG-2 promoter construct with mutations at the c-Myb site was not enriched in the ChIP assay, while a wild-type integrated promoter construct was enriched. Finally, this lack of binding of c-Myb to a chromosomally integrated mutant RAG-2 promoter construct in vivo was associated with a striking decrease in promoter activity. We conclude that c-Myb regulates the RAG-2 promoter in T cells by binding to this consensus c-Myb binding site.